These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36624559)

  • 1. Non-invasive diagnosis of transthyretin cardiac amyloidosis utilizing typical late gadolinium enhancement pattern on cardiac magnetic resonance and light chains.
    Slivnick JA; Alvi N; Singulane CC; Scheetz S; Goyal A; Patel H; Sarswat N; Addetia K; Fernandes F; Vieira MLC; Cafezeiro CRF; Carvalhal SF; Simonetti OP; Singh J; Lang RM; Zareba KM; Patel AR
    Eur Heart J Cardiovasc Imaging; 2023 May; 24(6):829-837. PubMed ID: 36624559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study.
    Chatzantonis G; Bietenbeck M; Elsanhoury A; Tschöpe C; Pieske B; Tauscher G; Vietheer J; Shomanova Z; Mahrholdt H; Rolf A; Kelle S; Yilmaz A
    Clin Res Cardiol; 2021 Apr; 110(4):555-568. PubMed ID: 33170349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMR-based differentiation of AL and ATTR cardiac amyloidosis.
    Dungu JN; Valencia O; Pinney JH; Gibbs SD; Rowczenio D; Gilbertson JA; Lachmann HJ; Wechalekar A; Gillmore JD; Whelan CJ; Hawkins PN; Anderson LJ
    JACC Cardiovasc Imaging; 2014 Feb; 7(2):133-42. PubMed ID: 24412186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis.
    Kravchenko D; Isaak A; Zimmer S; Öztürk C; Mesropyan N; Bischoff LM; Voigt M; Ginzburg D; Attenberger U; Pieper CC; Kuetting D; Luetkens JA
    Eur Heart J Cardiovasc Imaging; 2024 Sep; 25(10):1451-1461. PubMed ID: 38912832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
    Ridouani F; Damy T; Tacher V; Derbel H; Legou F; Sifaoui I; Audureau E; Bodez D; Rahmouni A; Deux JF
    J Cardiovasc Magn Reson; 2018 Aug; 20(1):58. PubMed ID: 30115079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.
    Baggiano A; Boldrini M; Martinez-Naharro A; Kotecha T; Petrie A; Rezk T; Gritti M; Quarta C; Knight DS; Wechalekar AD; Lachmann HJ; Perlini S; Pontone G; Moon JC; Kellman P; Gillmore JD; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):69-80. PubMed ID: 31202744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.
    Briasoulis A; Lama N; Rempakos A; Theodorakakou F; Stamatelopoulos K; Dimopoulos MA; Kelekis N; Kastritis E
    Curr Probl Cardiol; 2023 Apr; 48(4):101573. PubMed ID: 36586704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
    Fontana M; Pica S; Reant P; Abdel-Gadir A; Treibel TA; Banypersad SM; Maestrini V; Barcella W; Rosmini S; Bulluck H; Sayed RH; Patel K; Mamhood S; Bucciarelli-Ducci C; Whelan CJ; Herrey AS; Lachmann HJ; Wechalekar AD; Manisty CH; Schelbert EB; Kellman P; Gillmore JD; Hawkins PN; Moon JC
    Circulation; 2015 Oct; 132(16):1570-9. PubMed ID: 26362631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis.
    Aquaro GD; Pugliese NR; Perfetto F; Cappelli F; Barison A; Masci PG; Passino C; Emdin M
    Int J Cardiovasc Imaging; 2014 Aug; 30(6):1105-15. PubMed ID: 24789582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.
    Syed IS; Glockner JF; Feng D; Araoz PA; Martinez MW; Edwards WD; Gertz MA; Dispenzieri A; Oh JK; Bellavia D; Tajik AJ; Grogan M
    JACC Cardiovasc Imaging; 2010 Feb; 3(2):155-64. PubMed ID: 20159642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.
    Ahmad O; Omer MH; Janjua M; Alayary I; Fathala A; Alsergani H; Alamro B; Damy T; Fadel B; Mohty D
    ESC Heart Fail; 2024 Dec; 11(6):4348-4359. PubMed ID: 39219298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac amyloidosis: in search of the ideal diagnostic tool.
    Mavrogeni SI; Vartela V; Ntalianis A; Vretou R; Ikonomidis I; Tselegkidou M; Paraskevaidis I; Markousis-Mavrogenis G; Noutsias M; Rigopoulos A; Kolovou G; Kastritis E
    Herz; 2021 Apr; 46(Suppl 1):9-14. PubMed ID: 31796976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.
    Dohy Z; Szabo L; Pozsonyi Z; Csecs I; Toth A; Suhai FI; Czimbalmos C; Szucs A; Kiss AR; Becker D; Merkely B; Vago H
    PLoS One; 2022; 17(6):e0269807. PubMed ID: 35696411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease.
    Mongeon FP; Jerosch-Herold M; Coelho-Filho OR; Blankstein R; Falk RH; Kwong RY
    JACC Cardiovasc Imaging; 2012 Sep; 5(9):897-907. PubMed ID: 22974802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing hypertensive cardiomyopathy from cardiac amyloidosis in hypertensive patients with heart failure: a CMR study with histological confirmation.
    Gil KE; Truong V; Liu C; Ibrahim DY; Mikrut K; Satoskar A; Varghese J; Kahwash R; Han Y
    Int J Cardiovasc Imaging; 2024 Dec; 40(12):2559-2570. PubMed ID: 39417970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.
    Palmer C; Truong VT; Slivnick JA; Wolking S; Coleman P; Mazur W; Zareba KM
    Sci Rep; 2022 Jan; 12(1):140. PubMed ID: 34996915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.
    Neculae G; Adam R; Jercan A; Bădeliță S; Tjahjadi C; Draghici M; Stan C; Bax JJ; Popescu BA; Marsan NA; Coriu D; Jurcuț R
    ESC Heart Fail; 2024 Oct; 11(5):2825-2834. PubMed ID: 38757395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
    Yue X; Yang L; Wang R; Chan Q; Yang Y; Wu X; Ruan X; Zhang Z; Wei Y; Wang F
    Front Cardiovasc Med; 2022; 9():1017097. PubMed ID: 36330005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.